Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma.
about
HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsEvaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistryInterleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma.Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisGenomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniquesCombination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoSystematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.An Integrative Analysis to Identify Driver Genes in Esophageal Squamous Cell CarcinomaEpidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinomaAnti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyTrastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse modelsCombined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expressionHuman epidermal growth factor receptor-2 in oesophageal cancers: an observational study.Expression levels of HER2 and MRP1 are not prognostic factors of long-term survival in 829 patients with esophageal squamous cell carcinomaTargeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinomaGene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma.Esophageal cancer: current and emerging therapy modalities.ErbB receptors in the biology and pathology of the aerodigestive tractThe MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer.Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.Advances in biomarkers for esophageal cancer.Gene expression profiles of phaeochromocytomas with ERBB2 overexpression reveal a new molecular mechanism tumourigenicity.Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma.Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review.Correlation among 16 biological factors [p53, p21(waf1), MIB-1 (Ki-67), p16(INK4A), cyclin D1, E-cadherin, Bcl-2, TNF-α, NF-κB, TGF-β, MMP-7, COX-2, EGFR, HER2/neu, ER, and HIF-1α] and clinical outcomes following curative chemoradiation therapy in 1Targeted treatments for metastatic esophageal squamous cell cancerHER2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus.Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma.Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.Clinical impact of predicting CCND1 amplification using plasma DNA in superficial esophageal squamous cell carcinoma.Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies.Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer.
P2860
Q28078111-3C29FCB1-4A88-4385-8BB5-8CEF75DFC59CQ33398141-09235F02-C311-49B9-8F4A-C0D170D88015Q33658562-6AA3E829-BFB7-462C-BAC5-AEE3B4E760D4Q33868284-9415C86A-6FF1-4773-8311-6FC4FFCECC40Q34493341-7277A7AA-C0FA-4BB1-80FE-191C406E0926Q34565285-96AC20B1-9138-449A-BB31-E8F347CA45F4Q34787422-121A9FCA-65B3-4894-81E1-BF34EB202479Q35037270-3C02BFFB-AA28-4F27-BB19-8CAED60A2554Q35218636-474B1560-ECFD-49AC-88DB-F168CEA87ACAQ35805987-48CC0669-C1FF-4CD7-A5EC-B6263D0E4448Q35870351-AC6C4898-7C11-4290-9B1C-AAFD19123A3FQ36101895-3C56D4FC-36DA-4FAA-9490-51A9D0756B99Q36116250-B698A147-0D3C-476F-A13A-03973B9F60BCQ36361515-33DCBCDE-1718-4A69-B964-F4D0D0076157Q36388501-0500B3A4-FBA4-4AF8-91FA-B7DFAAFC6A8FQ36388523-1C283AF8-1C84-423F-BCEB-E9354A6E20FEQ36429835-A4510FDF-9BA8-48E7-857D-1E323872D7CEQ36503276-87344069-4746-415B-B4B7-7A986012E70EQ36611021-50A448AD-6AA2-4823-9CBF-A97F5059F8E9Q36755676-E5B41486-8838-4872-91F0-F24F7C3A859CQ37256825-BABA30C3-861F-4F47-812C-57D26C4E2F4DQ37263452-09A2FE8A-3731-458A-B1A6-16BAD4BD15A6Q37377808-75760531-EF0C-47D0-971B-322174006418Q37522215-1CACAD65-578B-4E58-877C-A9AA219A2A06Q38030442-17CB924B-061B-4515-A174-46B4C8805C6CQ38073827-DBED24FB-A94F-463C-8B64-5EBE920C47E5Q38153443-D0FE0CEC-5CBE-42F1-9C79-15E46A62ECF9Q38497926-A943A293-4820-45A4-BB9F-D8E8E097EB3DQ38613413-76F9D295-C3E6-4714-AAE7-91DE3A51B9ACQ39612011-E15AF505-4F26-4F11-BC5E-6234B535F86DQ39680556-CD525231-B9AF-40E4-A889-06C6158F539BQ41451463-2F3A0E85-9F4F-498A-A953-AF433CA1770DQ42148256-751CC65C-0953-496B-A094-EC610519FB22Q42154615-B38E71B4-0C99-4213-8BEF-596245A77B7EQ43096851-EF52D07D-701D-4F35-8376-558EAC079B60Q51056791-B9ACE9E5-D70E-4D8F-A1F7-75E43C390A49Q51512708-4A627502-D416-4B6F-A71B-26A81079DCD6Q53070828-743E06A6-E929-47E4-9C39-AF695FC6AA65Q54111164-FF35A9A6-8DA1-43E3-AB55-7C482FD75CFEQ54501568-36E57384-2C79-4C59-86A9-45AA5EBBD077
P2860
Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Frequencies of HER-2/neu expre ...... ageal squamous cell carcinoma.
@ast
Frequencies of HER-2/neu expre ...... ageal squamous cell carcinoma.
@en
type
label
Frequencies of HER-2/neu expre ...... ageal squamous cell carcinoma.
@ast
Frequencies of HER-2/neu expre ...... ageal squamous cell carcinoma.
@en
prefLabel
Frequencies of HER-2/neu expre ...... ageal squamous cell carcinoma.
@ast
Frequencies of HER-2/neu expre ...... ageal squamous cell carcinoma.
@en
P2093
P2860
P356
P1476
Frequencies of HER-2/neu expre ...... ageal squamous cell carcinoma.
@en
P2093
N Miyagawa
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602499
P407
P577
2005-04-01T00:00:00Z